The 5th Annual Think Tank on Advancing Precision Medicine in Rare Cancers, organized by TargetCancer Foundation, took place on November 12, 2026, in Boston, Massachusetts, bringing together key stakeholders for interactive discussions on challenges in rare cancer treatment development and policy. The meeting explored patient-centric clinical trials, tissue-agnostic therapies, emerging treatment strategies, and the need for greater advocacy, research funding, and policy change.
The program also featured a scientific keynote by Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented on the evolving role of RAS-targeted strategies in pancreatic cancer and other RAS-driven rare cancers. The meeting also marked the launch of the TargetCancer Foundation Think Tank Accelerator Program, a new initiative aimed at fostering collaboration in rare cancer research, and recognized early-career investigators through the 2026 Evan Schumacher Fund for Rare Cancer Research Early Investigator Award.
Vivek Subbiah, also delivered a lecture during the meeting. Ahead of his presentation, he shared on X:
“One of my favorite meetings of the year is today: Target Cancer Foundation’s Rare Cancer Precision Oncology meeting.
Looking forward to delivering my lecture ‘AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, and the Next Frontier.'”
You can alos read: Yu Fujiwara Thanks TargetCancer Foundation for Bringing Together the Rare Cancer and Tumor-Agnostic Research Community
